ADQUEY (Difamilast) Patent Expiration, LOE Window & CMS Spending

ADQUEY (Difamilast) by Aurobindo Pharma: FDA Orange Book core substance LOE 2036-12-31, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $1,143 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAurobindo Pharma
FDA Application & PathwayN219474 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-12-31
Last Listed Patent or Exclusivity Date2036-12-31
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,143 intro WAC)